TY - JOUR
T1 - (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido)pentyl) ureido)-pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy
AU - Kiess, Ana P.
AU - Minn, Il
AU - Vaidyanathan, Ganesan
AU - Hobbs, Robert F.
AU - Josefsson, Anders
AU - Shen, Colette
AU - Brummet, Mary
AU - Chen, Ying
AU - Choi, Jaeyeon
AU - Koumarianou, Eftychia
AU - Baidoo, Kwamena
AU - Brechbiel, Martin W.
AU - Mease, Ronnie C.
AU - Sgouros, George
AU - Zalutsky, Michael R.
AU - Pomper, Martin G.
N1 - Publisher Copyright:
Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.
AB - Alpha-particle emitters have a high linear energy transfer and short range, offering the potential for treating micrometastases while sparing normal tissues. We developed a urea-based, 211At-labeled small molecule targeting prostate-specific membrane antigen (PSMA) for the treatment of micrometastases due to prostate cancer (PC). Methods: PSMA-targeted (2S)-2-(3-(1-carboxy-5-(4-211At-astatobenzamido) pentyl)ureido)-pentanedioic acid (211At-6) was synthesized. Cellular uptake and clonogenic survival were tested in PSMA-positive (PSMA+) PC3 PIP and PSMA-negative (PSMA-) PC3 flu human PC cells after 211At-6 treatment. The antitumor efficacy of 211At-6 was evaluated in mice bearing PSMA+ PC3 PIP and PSMA- PC3 flu flank xenografts at a 740-kBq dose and in mice bearing PSMA+, luciferase-expressing PC3-ML micrometastases. Biodistribution was determined in mice bearing PSMA+ PC3 PIP and PSMA-PC3 flu flank xenografts. Suborgan distribution was evaluated using α-camera images, and microscale dosimetry was modeled. Long-term toxicity was assessed in mice for 12 mo. Results: 211At-6 treatment resulted in PSMA-specific cellular uptake and decreased clonogenic survival in PSMA+ PC3 PIP cells and caused significant tumor growth delay in PSMA+ PC3 PIP flank tumors. Significantly improved survival was achieved in the newly developed PSMA+ micrometastatic PC model. Biodistribution showed uptake of 211At-6 in PSMA+ PC3 PIP tumors and in kidneys. Microscale kidney dosimetry based on α-camera images and a nephron model revealed hot spots in the proximal renal tubules. Long-term toxicity studies confirmed that the dose-limiting toxicity was late radiation nephropathy. Conclusion: PSMA-targeted 211At-6 α-particle radiotherapy yielded significantly improved survival in mice bearing PC micrometastases after systemic administration. 211At-6 also showed uptake in renal proximal tubules resulting in late nephrotoxicity, highlighting the importance of long-term toxicity studies and microscale dosimetry.
KW - Alpha emitter
KW - Astatine
KW - Oncology: GU
KW - Prostate cancer
KW - Prostate-specific membrane antigen
KW - Radiation dosimetry
KW - Radionuclide therapy
KW - Radiopharmaceuticals
UR - http://www.scopus.com/inward/record.url?scp=84991376228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991376228&partnerID=8YFLogxK
U2 - 10.2967/jnumed.116.174300
DO - 10.2967/jnumed.116.174300
M3 - Article
C2 - 27230930
AN - SCOPUS:84991376228
SN - 0161-5505
VL - 57
SP - 1569
EP - 1575
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 10
ER -